Joinn Laboratories (China) Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Beijing Zhaoyan New Drug Research Center Co., Ltd. (stock code: 603127. SH/6127. HK) is the earliest private CRO enterprise in China engaged in non clinical drug evaluation. Since its establishment in 1995, it has a professional technical team of over 2500 people and has subsidiaries in Beijing, Suzhou, Chongqing, Guangzhou, Wuxi, Wuzhou, Nanning, Yunnan, Shanghai, California, and Boston. The company is located in the Economic and Technological Development Zone (Yizhuang) of Beijing, established in August 1995. It is a national "12th Five Year Plan Major New Drug Creation" platform and a key laboratory for drug safety evaluation in Beijing. Zhaoyan (Beijing) has a facility area of 11600m2, including 5000m2 of animal feeding and management facilities, equipped with ordinary level, SPF level animal rooms, and biosafety level II (P2) cell rooms. Zhaoyan (Beijing) passed NMPA's GLP certification for the first time in 2005, international AAALAC certification in 2008, on-site GLP inspection by the US FDA in 2009, and another GLP inspection by the US FDA in 2013. Zhaoyan is one of the units in China that has conducted the most trials and evaluated the largest number of Class 1 new drugs, and has established a complete and systematic drug evaluation technology capability. |
| Headquarter | Beijing |
| Establish Date | 2/25/1998 |
| Listed Code | 603127.SH |
| Listed Date | 8/25/2017 |
| Chairman | Feng Yuxia. |
| CEO | Gao Dapeng. |
| Website | www.joinnlabs.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
